| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8506929 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(3 years from now) | |
| US7687052 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(3 years from now) | |
Amyvid is owned by Avid Radiopharms Inc.
Amyvid contains Florbetapir F-18.
Amyvid has a total of 2 drug patents out of which 0 drug patents have expired.
Amyvid was authorised for market use on 06 April, 2012.
Amyvid is available in solution;intravenous dosage forms.
Amyvid can be used as amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment.
Drug patent challenges can be filed against Amyvid from 06 April, 2016.
The generics of Amyvid are possible to be released after 30 April, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2017 |
Drugs and Companies using FLORBETAPIR F-18 ingredient
NCE-1 date: 06 April, 2016
Market Authorisation Date: 06 April, 2012
Treatment: Amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION;INTRAVENOUS
AMYVID family patents
